Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.34 |
| ▸ | RPS6KA1 | Q15418 | 5/20 | 0.34 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.33 |
| ▸ | CCNK | O75909 | 2/20 | 0.33 |
| ▸ | CDK9 | P50750 | 2/20 | 0.33 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2022964 | 0.87 | PIM1 (0.35) | CCNT1CCNKCDK9CDK2 | |
| SCHEMBL3236457 | 0.82 | MAPK1 (0.37) | MAPK1RPS6KA1MAPK3CCNT1CDK9 | |
| SCHEMBL2021521 | 0.82 | PDE10A (0.45) | PDE4DCCNE1CDK2PDE4B | |
| SCHEMBL2022499 | 0.76 | TSHR (0.39) | MAPK1 | |
| SCHEMBL3240488 | 0.73 | PIM1 (0.37) | MAPK3CCNT1CDK9CDK2 | |
| SCHEMBL3240478 | 0.73 | PIM1 (0.37) | MAPK3CCNT1CDK9CDK2 | |
| SCHEMBL2019862 | 0.72 | MAPK1 (0.36) | PDE4DMAPK1RPS6KA1MAPK3CCNT1 | |
| SCHEMBL2021429 | 0.70 | NUDT1 (0.46) | PDE4DCDK2PDE4B | |
| SCHEMBL3199851 | 0.69 | OPRK1 (0.51) | MAPK1CCNT1 | |
| SCHEMBL3713155 | 0.68 | TDP1 (0.41) | MAPK1RPS6KA1MAPK3CCNT1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350027-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20110160206-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160206-A1 | TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PDE10A, PDE12, PDE9A | PDE4D 21/4885MAPK1 985/4885RPS6KA1 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.